Kate Ashton
Senior Scientist at Amgen, Inc
Dr. Kate Ashton received a Masters in Chemistry with Industrial Experience from the University of Edinburgh. She conducted her PhD thesis research on the synthesis and structure elucidation of Reidispongiolide A with Prof. Ian Paterson at the University of Cambridge, and her postdoctoral work on SOMO catalysis with Prof. David W. C. MacMillan at both Caltech and Princeton.
She has been at Amgen for 6 years and has worked on indications for cancer, Alzheimer’s and diabetes.Dr Fecke works in the area of industrial early drug discovery since 1996. He is currently Group Leader in the Primary Pharmacology department at UCB Pharma (UK) and is involved in the identification and characterization of NCE and NBE drugs in molecular interaction assays for both immunological and CNS diseases.
Prior to joining UCB, he worked for Novartis and Siena Biotech in the areas of transplant rejection, neurodegeneration and oncology. He obtained his PhD at the Heinrich-Heine-University Dusseldorf in Germany in 1994.
AMG-3969
M.Wt: 522.46
Cas : 1361224-53-4 , MF: C21H20F6N4O3S
Cas : 1361224-53-4 , MF: C21H20F6N4O3S
WO 2012027261 PRODUCT PATENT
2-[4-[(2S)-4-[(6-Amino-3-pyridinyl)sulfonyl]-2-(1-propyn-1-yl)-1-piperazinyl]phenyl]-1,1,1,3,3,3-hexafluoro-2-propanol)
MAKING CONNECTIONS Aleksandra Baranczak (right), a fourth-year grad student in Gary A. Sulikowski’s lab at Vanderbilt University, discusses her efforts to synthesize the core of the diazo-containing natural product lomaiviticin A with Kate Ashton, a medicinal chemist at Amgen
Experience
Senior Scientist
Amgen, Inc.
Postdoctoral Fellow
Princeton University
Postdoctoral Fellow
California Institute of Technology
Research Associate
Merck, UK
Education
University of Cambridge
Doctor of Philosophy (PhD), Organic Chemistry
Edinburgh University
Masters with Industrial Experience, Organic Chemistry
///////////
